Treatment of mild to moderate pemphigus with the use of rituximab and topical corticosteroids
- 26 October 2026
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line TherapyJAMA Dermatology, 2024
- Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effectBritish Journal of Dermatology, 2019
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017
- First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical CorticosteroidsJAMA Dermatology, 2015
- The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroidBritish Journal of Dermatology, 1999